See more : Ross River Minerals Inc. (RRMLF) Income Statement Analysis – Financial Results
Complete financial analysis of Jounce Therapeutics, Inc. (JNCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jounce Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Taisei Corporation (TISCF) Income Statement Analysis – Financial Results
- Trabzonspor Sportif Yatirim ve Futbol Isletmeciligi Ticaret A.S. (TSPOR.IS) Income Statement Analysis – Financial Results
- Jersey Electricity plc (JEL.L) Income Statement Analysis – Financial Results
- Comstock Resources, Inc. (CRK) Income Statement Analysis – Financial Results
- Nickel Industries Limited (NICMF) Income Statement Analysis – Financial Results
Jounce Therapeutics, Inc. (JNCE)
About Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 82.00M | 26.91M | 62.34M | 147.87M | 65.20M | 71.64M | 37.20M | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 82.00M | 26.91M | 62.34M | 147.87M | 65.20M | 71.64M | 37.20M | 0.00 | 0.00 |
Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
Research & Development | 103.27M | 88.98M | 78.69M | 67.14M | 70.05M | 67.80M | 34.90M | 22.13M | 11.24M |
General & Administrative | 30.97M | 28.98M | 28.77M | 27.92M | 26.44M | 23.06M | 16.76M | 8.27M | 4.97M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 30.97M | 28.98M | 28.77M | 27.92M | 26.44M | 23.06M | 16.76M | 8.27M | 4.97M |
Other Expenses | 1.46M | 199.00K | 1.29M | 4.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 134.24M | 117.96M | 107.46M | 95.06M | 96.50M | 90.86M | 51.66M | 30.40M | 16.21M |
Cost & Expenses | 134.24M | 117.96M | 107.46M | 95.06M | 96.50M | 90.86M | 51.66M | 30.40M | 16.21M |
Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 2.09M | 2.83M | 3.40M | 3.85M | 3.83M | 4.42M | 1.94M | 1.47M | 1.11M |
EBITDA | -50.16M | -91.06M | -45.12M | 52.82M | -23.50M | -11.99M | -11.76M | -27.06M | -9.41M |
EBITDA Ratio | -61.16% | -338.41% | -72.37% | 35.72% | -36.05% | -16.73% | -31.61% | 0.00% | 0.00% |
Operating Income | -52.24M | -91.06M | -45.12M | 52.82M | -31.29M | -19.22M | -14.47M | -30.40M | -16.21M |
Operating Income Ratio | -63.71% | -338.41% | -72.37% | 35.72% | -48.00% | -26.82% | -38.89% | 0.00% | 0.00% |
Total Other Income/Expenses | 1.46M | 199.00K | 1.29M | 4.05M | 3.96M | 2.81M | 763.00K | 1.86M | 5.70M |
Income Before Tax | -50.78M | -90.86M | -43.83M | 56.87M | -27.33M | -16.41M | -13.70M | -28.53M | -10.52M |
Income Before Tax Ratio | -61.93% | -337.67% | -70.31% | 38.46% | -41.92% | -22.90% | -36.84% | 0.00% | 0.00% |
Income Tax Expense | 135.00K | 15.00K | 14.00K | 46.00K | 46.00K | 36.00K | 763.00K | 1.86M | 5.70M |
Net Income | -50.92M | -90.87M | -43.84M | 56.82M | -27.38M | -16.44M | -13.70M | -28.53M | -10.52M |
Net Income Ratio | -62.10% | -337.73% | -70.33% | 38.43% | -41.99% | -22.95% | -36.84% | 0.00% | 0.00% |
EPS | -0.99 | -1.82 | -1.24 | 1.72 | -0.84 | -0.55 | -0.45 | -1.54 | -0.48 |
EPS Diluted | -0.99 | -1.82 | -1.24 | 1.66 | -0.84 | -0.55 | -0.45 | -1.54 | -0.48 |
Weighted Avg Shares Out | 51.68M | 49.93M | 35.43M | 33.08M | 32.57M | 30.06M | 30.16M | 18.52M | 22.09M |
Weighted Avg Shares Out (Dil) | 51.68M | 49.93M | 35.43M | 34.29M | 32.57M | 30.06M | 30.16M | 18.52M | 22.09M |
Jounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply Source
Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer
Penny Stocks To Buy Now: 7 To Watch Before Next Week
Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences
5 Top Penny Stocks To Buy In March According To Insiders
Navigating Volatile Penny Stocks: Essential Tips for Investors
Tang Capital Partners Now Owns 10.2% of Jounce Therapeutics
Why Is Jounce Therapeutics (JNCE) Stock Up 37% Today?
Maximizing Returns With Penny Stocks: Day Trading
Why Is Jounce Therapeutics (JNCE) Stock Up 14% Today?
Source: https://incomestatements.info
Category: Stock Reports